Catalyst Pharmaceuticals (CPRX) Financials

$24.49 +0.38 (+1.58%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$24.34 -0.15 (-0.59%)

As of 05/23/2025 07:43 PM Eastern

Annual Income Statements for Catalyst Pharmaceuticals

This table shows Catalyst Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	164	71	83	39	75	32	-34	-18	-18	-20
Consolidated Net Income / (Loss)	164	71	83	39	75	32	-34	-18	-18	-20
Net Income / (Loss) Continuing Operations	164	71	83	39	75	32	-34	-18	-18	-20
Total Pre-Tax Income	216	95	105	53	42	33	-34	-18	-18	-20
Total Operating Income	195	87	102	52	41	32	-35	-19	-19	-20
Total Gross Profit	423	346	180	119	102	88	0.50	0.00	0.00	0.00
Total Revenue	492	398	214	141	119	102	0.50	0.00	0.00	0.00
Operating Revenue	492	398	214	141	119	102	0.50	0.00	0.00	0.00
Total Cost of Revenue	69	52	34	22	17	15	0.00	0.00	0.00	0.00
Operating Cost of Revenue	69	52	34	22	17	15	0.00	-	-	-
Total Operating Expenses	228	259	78	67	61	56	36	19	19	20
Selling, General & Admin Expense	178	134	57	50	44	37	16	7.30	7.91	8.60
Research & Development Expense	13	93	20	17	16	19	20	11	11	12
Amortization Expense	37	33	1.10	0.00	-	-	-	-	-	-
Total Other Income / (Expense), net	21	7.70	2.88	0.28	0.59	1.59	1.29	0.27	1.21	0.17
Other Income / (Expense), net	21	7.70	2.88	0.28	0.59	1.59	1.29	0.27	1.21	0.17
Income Tax Expense	52	23	22	13	-33	1.53	0.00	0.00	0.00	0.00
Basic Earnings per Share	$1.38	$0.67	$0.80	$0.38	$0.72	$0.31	($0.33)	($0.21)	($0.22)	($0.25)
Weighted Average Basic Shares Outstanding	118.46M	106.28M	103.37M	103.38M	103.51M	102.94M	102.63M	85.80M	82.88M	80.86M
Diluted Earnings per Share	$1.31	$0.63	$0.75	$0.37	$0.71	$0.30	($0.33)	($0.21)	($0.22)	($0.25)
Weighted Average Diluted Shares Outstanding	124.94M	113.75M	111.38M	107.80M	106.24M	106.02M	102.63M	85.80M	82.88M	80.86M
Weighted Average Basic & Diluted Shares Outstanding	121.45M	117.86M	105.65M	102.74M	103.82M	103.41M	102.63M	85.80M	82.88M	80.86M

This table shows Catalyst Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	57	56	44	41	23	35	-31	38	30	25	23
Consolidated Net Income / (Loss)	57	56	44	41	23	35	-31	38	30	25	23
Net Income / (Loss) Continuing Operations	57	56	44	41	23	35	-31	38	30	25	23
Total Pre-Tax Income	71	74	57	56	29	47	-38	49	37	33	26
Total Operating Income	63	63	51	54	27	42	-37	47	36	31	25
Total Gross Profit	124	120	109	107	86	95	89	88	75	50	48
Total Revenue	141	142	129	123	99	111	103	100	85	61	57
Operating Revenue	141	142	129	123	99	111	103	100	85	61	57
Total Cost of Revenue	18	22	19	15	13	16	14	12	9.95	11	9.67
Operating Cost of Revenue	18	22	19	15	13	16	14	12	9.95	11	9.67
Total Operating Expenses	60	57	59	53	59	53	126	41	40	19	22
Selling, General & Admin Expense	47	44	46	41	47	42	34	28	30	14	14
Research & Development Expense	3.89	3.80	3.28	2.99	2.58	1.97	84	3.95	3.56	4.09	8.31
Amortization Expense	9.35	9.34	9.35	9.34	9.34	9.06	8.49	8.49	6.53	0.58	0.52
Total Other Income / (Expense), net	7.92	11	6.30	1.54	1.96	5.02	-0.83	1.81	1.70	2.21	0.91
Other Income / (Expense), net	7.92	11	6.30	1.54	1.96	5.02	-0.83	1.81	1.70	2.21	0.91
Income Tax Expense	15	18	13	15	5.81	12	-7.26	11	7.75	7.54	3.26
Basic Earnings per Share	$0.47	$0.46	$0.37	$0.35	$0.20	$0.32	($0.29)	$0.36	$0.28	$0.24	$0.22
Weighted Average Basic Shares Outstanding	121.47M	118.46M	118.93M	118.18M	116.81M	106.28M	106.57M	106.26M	105.56M	103.37M	103.32M
Diluted Earnings per Share	$0.45	$0.44	$0.35	$0.33	$0.19	$0.33	($0.29)	$0.33	$0.26	$0.23	$0.20
Weighted Average Diluted Shares Outstanding	126.96M	124.94M	125.41M	124.66M	123.40M	113.75M	106.57M	113.67M	113.99M	111.38M	111.99M
Weighted Average Basic & Diluted Shares Outstanding	121.98M	121.45M	119.27M	118.69M	118.12M	117.86M	106.61M	106.58M	106.08M	105.65M	104.07M

This table details how cash moves in and out of Catalyst Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	380	-161	127	41	41	73	-41	44	-14	19
Net Cash From Operating Activities	240	144	116	60	45	35	-26	-14	-18	-18
Net Cash From Continuing Operating Activities	240	144	116	60	45	35	-26	-14	-18	-18
Net Income / (Loss) Continuing Operations	164	71	83	39	75	32	-34	-18	-18	-20
Consolidated Net Income / (Loss)	164	71	83	39	75	32	-34	-18	-18	-20
Depreciation Expense	0.40	0.32	0.14	0.19	0.09	0.06	0.04	0.05	0.04	0.03
Amortization Expense	37	33	1.10	0.00	0.00	0.24	0.00	-	-	-
Non-Cash Adjustments To Reconcile Net Income	16	94	13	7.22	6.12	3.26	3.11	2.59	0.95	1.52
Changes in Operating Assets and Liabilities, net	22	-55	19	13	-36	-0.82	4.71	2.03	-0.88	0.66
Net Cash From Investing Activities	-0.56	-294	9.21	-11	-5.01	37	-15	-0.00	3.55	-0.01
Net Cash From Continuing Investing Activities	-0.56	-294	9.21	-11	-5.01	37	-15	-0.00	3.55	-0.01
Purchase of Property, Plant & Equipment	-0.56	-0.23	-0.03	-1.02	-0.01	-0.02	-0.09	-	-0.10	-0.02
Acquisitions	0.00	-280	-10	0.00	-	-	-	-	-	-
Sale and/or Maturity of Investments	0.00	0.00	19	0.00	5.00	72	22	-	-	0.02
Other Investing Activities, net	0.00	-13	0.00	0.00	0.00	-	-	-	3.72	-0.00
Net Cash From Financing Activities	141	-11	1.69	-8.14	0.70	1.12	0.29	57	0.07	37
Net Cash From Continuing Financing Activities	141	-11	1.69	-8.14	0.70	1.12	0.29	57	0.07	37
Repurchase of Common Equity	-0.30	0.00	-6.91	-12	0.00	0.00	-	-	-	-
Issuance of Common Equity	141	0.00	0.00	-	-	-	-	54	-	35
Other Financing Activities, net	-0.04	-11	8.60	3.95	0.70	1.12	0.29	3.58	0.07	2.29
Cash Interest Paid	1.40	0.71	0.00	0.00	-	-	-	-	-	-
Cash Income Taxes Paid	68	50	7.67	3.00	2.79	0.00	0.00	-	-	-

This table details how cash moves in and out of Catalyst Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	63	75	67	65	173	17	-58	31	-150	42	45
Net Cash From Operating Activities	60	71	73	64	32	56	45	31	12	40	41
Net Cash From Continuing Operating Activities	60	71	73	64	32	56	45	31	12	40	41
Net Income / (Loss) Continuing Operations	57	56	44	41	23	35	-31	38	30	25	23
Consolidated Net Income / (Loss)	57	56	44	41	23	35	-31	38	30	25	23
Depreciation Expense	0.12	0.11	0.11	0.09	0.09	0.08	0.08	0.08	0.07	0.04	0.04
Amortization Expense	9.35	9.34	9.35	9.34	9.34	9.06	8.49	8.49	6.53	0.58	0.52
Non-Cash Adjustments To Reconcile Net Income	3.12	-1.61	1.56	6.78	9.52	3.04	85	3.45	3.00	1.91	6.31
Changes in Operating Assets and Liabilities, net	-9.28	7.10	18	7.13	-10	8.62	-17	-19	-27	12	12
Net Cash From Investing Activities	0.00	-0.09	-0.26	-0.01	-0.20	-38	-93	-	-162	-	-0.13
Net Cash From Continuing Investing Activities	0.00	-0.09	-0.26	-0.01	-0.20	-38	-93	-	-162	-	-0.13
Purchase of Property, Plant & Equipment	0.00	-0.09	-0.26	-0.01	-0.20	-0.09	-0.06	-	-0.07	-	-
Acquisitions	0.00	-	-	-	0.00	-38	-79	-	-162	-	-10
Purchase of Investments	0.00	-	-	-	-	-	-	-	-	-	-
Net Cash From Financing Activities	3.06	4.43	-5.97	1.16	141	-0.67	-10	-0.21	0.15	2.25	3.98
Net Cash From Continuing Financing Activities	3.06	4.43	-5.97	1.16	141	-0.67	-10	-0.21	0.15	2.25	3.98
Repurchase of Common Equity	0.00	-	-	-	-0.30	-	-	-	0.00	-	-
Issuance of Common Equity	0.00	-	-	-	141	-	-	-	0.00	-	-
Other Financing Activities, net	3.06	4.43	-5.97	1.16	0.35	-0.67	-10	-0.21	0.15	2.25	3.98
Cash Interest Paid	0.10	0.09	1.16	0.08	0.07	0.06	0.65	-	0.00	-	-
Cash Income Taxes Paid	0.64	17	18	-	-	8.80	14	-	-	1.32	0.50

This table presents Catalyst Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	851	470	376	238	192	112	60	85	42	60
Total Current Assets	624	219	321	210	159	111	55	85	41	60
Cash & Equivalents	518	138	298	171	130	90	17	57	14	28
Accounts Receivable	65	54	10	6.62	5.99	11	-	-	-	-
Inventories, net	20	16	6.81	7.87	4.65	1.96	0.06	0.00	-	-
Prepaid Expenses	21	13	5.17	4.35	8.33	4.35	1.65	1.17	1.05	1.50
Plant, Property, & Equipment, net	1.35	1.20	0.85	0.96	0.13	0.21	0.25	0.19	0.24	0.19
Total Noncurrent Assets	226	250	54	27	33	0.80	5.02	0.01	0.01	0.01
Long-Term Investments	22	16	0.00	-	-	-	5.01	0.00	-	-
Intangible Assets	157	194	32	0.00	-	-	-	-	-	-
Noncurrent Deferred & Refundable Income Taxes	46	37	19	24	33	0.00	-	-	-	-
Other Noncurrent Operating Assets	2.23	2.51	2.77	3.03	0.01	0.80	0.01	0.01	0.01	0.01
Total Liabilities & Shareholders' Equity	851	470	376	238	192	112	60	85	42	60
Total Liabilities	124	82	75	31	23	25	9.67	4.42	2.40	4.63
Total Current Liabilities	121	76	58	27	23	24	9.51	4.27	2.09	3.44
Accounts Payable	17	15	3.98	2.77	4.26	4.12	2.34	1.95	0.93	1.79
Accrued Expenses	104	61	54	24	19	20	7.17	2.32	1.16	1.65
Total Noncurrent Liabilities	3.10	6.17	18	3.89	0.00	0.65	0.15	0.16	0.30	1.18
Other Noncurrent Operating Liabilities	3.10	6.17	18	3.89	0.00	0.65	0.15	0.16	0.30	1.18
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	728	388	300	207	170	88	51	81	39	55
Total Preferred & Common Equity	728	388	300	207	170	88	51	81	39	55
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00
Total Common Equity	728	388	300	207	170	88	51	81	39	55
Common Stock	442	267	251	233	223	216	211	208	147	146
Retained Earnings	285	121	50	-26	-54	-129	-161	-127	-108	-90
Accumulated Other Comprehensive Income / (Loss)	0.06	0.01	0.02	-0.15	0.03	0.01	-0.02	-	-	-

This table presents Catalyst Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	909	772	706	647	413	444	407	333
Total Current Assets	686	539	474	405	192	241	199	276
Cash & Equivalents	581	442	376	310	121	179	148	256
Accounts Receivable	71	58	57	60	48	43	33	9.34
Inventories, net	20	20	18	20	9.04	11	10	7.13
Prepaid Expenses	14	18	24	14	14	8.63	6.93	3.78
Plant, Property, & Equipment, net	1.24	1.38	1.23	1.31	1.19	1.20	1.29	0.88
Total Noncurrent Assets	222	232	231	241	220	202	207	56
Long-Term Investments	24	15	13	15	13	-	-	-
Intangible Assets	147	166	175	185	167	176	184	33
Noncurrent Deferred & Refundable Income Taxes	48	48	40	38	37	23	20	20
Other Noncurrent Operating Assets	2.16	2.30	2.37	2.44	2.58	2.64	2.71	2.84
Total Liabilities & Shareholders' Equity	909	772	706	647	413	444	407	333
Total Liabilities	115	111	98	85	65	69	74	63
Total Current Liabilities	112	105	92	80	58	53	57	45
Accounts Payable	11	12	7.12	10	4.60	4.42	3.39	2.53
Accrued Expenses	100	94	85	69	53	48	53	42
Total Noncurrent Liabilities	2.94	5.67	5.39	5.70	6.86	16	17	18
Other Noncurrent Operating Liabilities	2.94	5.67	5.39	5.70	6.86	16	17	18
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	794	661	609	561	349	375	334	270
Total Preferred & Common Equity	794	661	609	561	349	375	334	270
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	794	661	609	561	349	375	334	270
Common Stock	452	432	423	417	262	258	254	246
Retained Earnings	342	229	185	145	86	117	79	24
Accumulated Other Comprehensive Income / (Loss)	-0.02	0.00	0.00	0.00	0.02	0.02	0.01	0.03

This table displays calculated financial ratios and metrics derived from Catalyst Pharmaceuticals' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	23.49%	85.90%	52.10%	18.27%	16.39%	20,361.20%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	99.41%	20.23%	100.45%	25.91%	24.55%	199.24%	-84.93%	-1.87%	10.74%	-30.46%
EBIT Growth	128.82%	-9.75%	98.83%	25.73%	25.39%	198.25%	-84.68%	-1.88%	10.68%	-30.46%
NOPAT Growth	125.44%	-18.81%	105.74%	-46.88%	143.50%	222.89%	-88.95%	3.11%	5.48%	-39.80%
Net Income Growth	129.50%	-14.05%	110.42%	-47.35%	135.24%	193.74%	-84.68%	-1.88%	10.68%	-30.46%
EPS Growth	107.94%	-16.00%	102.70%	-47.89%	136.67%	190.91%	-57.14%	4.55%	12.00%	-4.17%
Operating Cash Flow Growth	67.00%	23.74%	92.22%	34.06%	30.11%	232.37%	-90.27%	23.50%	0.29%	-39.20%
Free Cash Flow Firm Growth	216.24%	-276.12%	77.90%	40.56%	27.68%	247.35%	-80.26%	27.39%	0.47%	-81.07%
Invested Capital Growth	-19.35%	11,437.81%	-86.98%	-46.91%	525.62%	10.61%	-152.69%	-178.02%	62.44%	27.59%
Revenue Q/Q Growth	6.79%	14.30%	11.71%	5.46%	0.75%	40.75%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	12.28%	21.14%	24.39%	10.18%	-1.26%	219.71%	-36.63%	-7.17%	8.42%	-13.02%
EBIT Q/Q Growth	14.55%	16.95%	23.89%	8.42%	0.77%	218.06%	-36.61%	-7.12%	8.37%	-12.98%
NOPAT Q/Q Growth	12.37%	12.54%	21.81%	-5.00%	81.69%	238.36%	-35.94%	-6.85%	8.87%	-12.14%
Net Income Q/Q Growth	14.77%	15.11%	24.15%	-5.11%	4.91%	237.44%	-36.61%	-7.12%	8.37%	-12.98%
EPS Q/Q Growth	9.17%	18.87%	22.95%	-5.13%	4.41%	233.33%	-32.00%	-5.00%	12.00%	-8.70%
Operating Cash Flow Q/Q Growth	6.78%	12.16%	21.97%	11.18%	1.84%	147.79%	-19.80%	2.70%	1.21%	-3.75%
Free Cash Flow Firm Q/Q Growth	35.51%	-16.65%	23.76%	12.85%	396.22%	197.29%	-12.99%	6.54%	-0.25%	-0.96%
Invested Capital Q/Q Growth	-7.49%	8.89%	-85.50%	-34.79%	-0.67%	-92.90%	-195.66%	-40.06%	40.42%	-26.27%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	86.00%	86.95%	83.94%	84.46%	85.69%	85.57%	100.00%	0.00%	0.00%	0.00%
EBITDA Margin	51.66%	31.99%	49.47%	37.53%	35.26%	32.95%	-6,793.11%	0.00%	0.00%	0.00%
Operating Margin	39.68%	21.80%	47.54%	37.20%	34.69%	31.11%	-7,059.03%	0.00%	0.00%	0.00%
EBIT Margin	43.98%	23.73%	48.89%	37.40%	35.18%	32.66%	-6,800.70%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	33.33%	17.93%	38.79%	28.03%	62.97%	31.16%	-6,800.70%	0.00%	0.00%	0.00%
Tax Burden Percent	75.78%	75.56%	79.34%	74.97%	179.00%	95.41%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	24.22%	24.44%	20.66%	25.03%	-79.00%	4.59%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	70.04%	55.64%	918.58%	174.98%	659.19%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	65.41%	53.07%	917.64%	174.86%	658.30%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-40.65%	-34.89%	-885.82%	-154.01%	-600.89%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	29.38%	20.75%	32.76%	20.98%	58.30%	46.06%	-51.62%	-30.62%	-38.13%	-44.61%
Cash Return on Invested Capital (CROIC)	91.46%	-140.92%	1,072.51%	236.27%	128.66%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	32.73%	22.35%	34.14%	24.49%	27.49%	38.66%	-46.63%	0.00%	0.00%	0.00%
Return on Assets (ROA)	24.80%	16.89%	27.09%	18.36%	49.21%	36.89%	-46.63%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	29.38%	20.75%	32.76%	20.98%	58.30%	46.06%	-51.62%	-30.62%	-38.13%	-44.61%
Return on Equity Simple (ROE_SIMPLE)	22.52%	18.41%	27.65%	19.09%	44.21%	36.37%	-66.96%	-22.74%	-45.98%	-36.47%
Net Operating Profit after Tax (NOPAT)	148	66	81	39	74	30	-25	-13	-13	-14
NOPAT Margin	30.07%	16.47%	37.72%	27.88%	62.09%	29.68%	-4,941.32%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	4.62%	2.57%	0.93%	0.13%	0.90%	1.98%	-13.05%	-8.58%	-9.26%	-12.19%
Return On Investment Capital (ROIC_SIMPLE)	20.32%	16.91%	26.89%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	14.00%	13.05%	16.06%	15.54%	14.31%	14.43%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	36.15%	33.58%	26.65%	35.24%	37.15%	36.05%	3,175.19%	0.00%	0.00%	0.00%
R&D to Revenue	2.57%	23.39%	9.24%	12.03%	13.85%	18.42%	3,983.84%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	46.32%	65.15%	36.40%	47.26%	51.00%	54.47%	7,159.03%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	216	95	105	53	42	33	-34	-18	-18	-20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	254	127	106	53	42	34	-34	-18	-18	-20
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.42	4.62	6.44	3.38	2.04	4.41	3.88	4.12	2.21	3.66
Price to Tangible Book Value (P/TBV)	4.36	9.25	7.22	3.38	2.04	4.41	3.88	4.12	2.21	3.66
Price to Revenue (P/Rev)	5.06	4.50	9.04	4.96	2.91	3.78	394.52	0.00	0.00	0.00
Price to Earnings (P/E)	15.19	25.10	23.30	17.68	4.62	12.12	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	6.58%	3.98%	4.29%	5.66%	21.66%	8.25%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	10.34	7.01	808.16	32.56	7.02	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	3.97	4.11	7.64	3.60	1.73	2.85	277.54	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	7.68	12.86	15.45	9.59	4.90	8.66	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	9.02	17.33	15.64	9.62	4.92	8.74	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	13.19	24.97	20.27	12.91	2.79	9.61	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	8.13	11.41	14.11	8.40	4.57	8.43	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	10.10	0.00	17.36	9.56	5.46	9.88	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.62	-0.66	-0.97	-0.88	-0.91	-1.11	-1.08	-1.03	-1.04	-1.08
Leverage Ratio	1.18	1.23	1.21	1.14	1.18	1.25	1.11	1.06	1.07	1.15
Compound Leverage Factor	1.18	1.23	1.21	1.14	1.18	1.25	1.11	1.06	1.07	1.15
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	14.66	15.31	17.96	15.62	10.93	10.59	7.58	43.55	17.84	24.24
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.17	2.88	5.57	7.76	7.00	4.62	5.80	19.97	19.79	17.41
Quick Ratio	4.83	2.51	5.36	7.31	6.43	4.36	5.62	19.69	19.29	16.97
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	193	-166	94	53	38	30	-20	-11	-15	-15
Operating Cash Flow to CapEx	43,130.94%	62,164.50%	400,162.07%	5,913.03%	409,400.00%	182,168.42%	-28,415.69%	0.00%	-18,700.10%	-76,774.86%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.74	0.94	0.70	0.65	0.78	1.18	0.01	0.00	0.00	0.00
Accounts Receivable Turnover	8.27	12.45	25.11	22.34	14.41	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	3.91	4.63	4.69	3.50	5.16	14.67	0.00	0.00	0.00	0.00
Fixed Asset Turnover	385.83	390.01	237.21	258.65	699.47	448.82	2.29	0.00	0.00	0.00
Accounts Payable Turnover	4.39	5.54	10.20	6.23	4.07	4.57	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	44.16	29.31	14.53	16.34	25.33	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	93.27	78.84	77.87	104.42	70.77	24.89	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	83.21	65.92	35.78	58.58	89.69	79.82	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	54.23	42.23	56.62	62.18	6.41	-54.93	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	189	234	2.03	16	29	-6.89	-7.71	-3.05	-1.10	-2.92
Invested Capital Turnover	2.33	3.38	24.35	6.28	10.62	-14.02	-0.09	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-45	232	-14	-14	36	0.82	-4.66	-1.95	1.82	1.11
Enterprise Value (EV)	1,950	1,638	1,637	507	206	292	139	249	47	145
Market Capitalization	2,489	1,792	1,936	698	346	386	197	333	87	203
Book Value per Share	$6.10	$3.64	$2.89	$2.01	$1.64	$0.85	$0.49	$0.95	$0.47	$0.67
Tangible Book Value per Share	$4.79	$1.82	$2.57	$2.01	$1.64	$0.85	$0.49	$0.95	$0.47	$0.67
Total Capital	728	388	300	207	170	88	51	81	39	55
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-539	-154	-298	-191	-140	-95	-58	-84	-40	-58
Capital Expenditures (CapEx)	0.56	0.23	0.03	1.02	0.01	0.02	0.09	0.00	0.10	0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-15	5.63	-35	-8.22	-3.79	-7.25	-7.81	-3.09	-1.05	-1.94
Debt-free Net Working Capital (DFNWC)	503	143	263	183	136	87	46	81	39	56
Net Working Capital (NWC)	503	143	263	183	136	87	46	81	39	56
Net Nonoperating Expense (NNE)	-16	-5.82	-2.29	-0.21	-1.05	-1.51	9.30	5.34	4.58	5.95
Net Nonoperating Obligations (NNO)	-539	-154	-298	-191	-140	-95	-58	-84	-40	-58
Total Depreciation and Amortization (D&A)	38	33	1.24	0.19	0.09	0.30	0.04	0.05	0.04	0.03
Debt-free, Cash-free Net Working Capital to Revenue	-2.97%	1.41%	-16.42%	-5.84%	-3.18%	-7.09%	-1,561.11%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	102.28%	35.98%	122.88%	129.97%	114.63%	85.30%	9,135.21%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	102.28%	35.98%	122.88%	129.97%	114.63%	85.30%	9,135.21%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.38	$0.67	$0.80	$0.38	$0.72	$0.31	($0.33)	($0.21)	($0.22)	($0.25)
Adjusted Weighted Average Basic Shares Outstanding	118.46M	106.28M	103.37M	103.38M	103.51M	102.94M	102.74M	102.56M	82.97M	82.88M
Adjusted Diluted Earnings per Share	$1.31	$0.63	$0.75	$0.37	$0.71	$0.30	($0.33)	($0.21)	($0.22)	($0.25)
Adjusted Weighted Average Diluted Shares Outstanding	124.94M	113.75M	111.38M	107.80M	106.24M	106.02M	102.74M	102.56M	82.97M	82.88M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	($0.33)	($0.21)	($0.22)	($0.25)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	121.45M	117.86M	105.65M	102.74M	103.82M	103.41M	102.63M	85.80M	82.88M	80.86M
Normalized Net Operating Profit after Tax (NOPAT)	148	66	81	39	29	30	-25	-13	-13	-14
Normalized NOPAT Margin	30.07%	16.47%	37.72%	27.88%	24.28%	29.68%	-4,941.32%	0.00%	0.00%	0.00%
Pre Tax Income Margin	43.98%	23.73%	48.89%	37.40%	35.18%	32.66%	-6,800.70%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.18%	0.00%	8.31%	30.62%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Catalyst Pharmaceuticals' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	43.56%	28.27%	25.33%	23.23%	15.40%	81.98%	79.39%	87.49%	98.12%	58.60%	59.21%
EBITDA Growth	109.63%	49.76%	326.31%	14.26%	-12.28%	66.11%	-210.89%	101.83%	151.03%	161.74%	88.33%
EBIT Growth	145.06%	58.82%	250.46%	15.00%	-22.04%	41.50%	-246.20%	71.75%	113.72%	157.61%	84.81%
NOPAT Growth	132.37%	52.36%	250.03%	9.12%	-23.08%	30.86%	-218.56%	66.24%	114.25%	156.74%	113.60%
Net Income Growth	143.77%	60.53%	242.65%	8.03%	-21.28%	36.80%	-235.24%	74.67%	123.31%	173.62%	120.23%
EPS Growth	136.84%	33.33%	220.69%	0.00%	-26.92%	43.48%	-245.00%	65.00%	116.67%	155.56%	100.00%
Operating Cash Flow Growth	88.08%	27.37%	61.48%	108.54%	164.50%	38.85%	9.27%	17.42%	42.37%	109.00%	90.27%
Free Cash Flow Firm Growth	438.75%	146.17%	122.04%	111.65%	78.83%	-637.77%	-811.90%	-496.95%	-616.42%	62.12%	99.94%
Invested Capital Growth	-19.62%	-19.35%	-5.08%	11.89%	27.10%	11,437.81%	1,436.06%	867.82%	726.82%	-86.98%	-41.45%
Revenue Q/Q Growth	-0.28%	10.20%	4.88%	24.57%	-10.91%	7.67%	3.12%	16.65%	40.50%	6.14%	7.78%
EBITDA Q/Q Growth	-3.46%	25.48%	2.20%	69.33%	-31.03%	289.62%	-151.60%	29.99%	30.60%	26.59%	-6.09%
EBIT Q/Q Growth	-3.90%	29.68%	2.54%	91.78%	-37.72%	222.85%	-178.37%	30.01%	13.04%	26.92%	-7.92%
NOPAT Q/Q Growth	6.43%	21.34%	-1.54%	82.76%	-30.22%	219.48%	-171.61%	28.82%	18.72%	8.25%	0.41%
Net Income Q/Q Growth	1.43%	27.46%	7.57%	75.27%	-33.20%	213.26%	-181.47%	27.71%	16.09%	11.97%	5.22%
EPS Q/Q Growth	2.27%	25.71%	6.06%	73.68%	-42.42%	213.79%	-187.88%	26.92%	13.04%	15.00%	0.00%
Operating Cash Flow Q/Q Growth	-15.29%	-2.74%	13.62%	100.89%	-42.63%	23.31%	46.74%	154.80%	-69.88%	-2.96%	57.69%
Free Cash Flow Firm Q/Q Growth	4.37%	85.38%	206.65%	157.10%	85.78%	11.51%	-62.13%	-3.77%	-461.25%	17.14%	-9.60%
Invested Capital Q/Q Growth	0.48%	-7.49%	-7.33%	-6.69%	0.81%	8.89%	9.25%	5.98%	9,051.73%	-85.50%	-31.17%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	87.34%	84.74%	85.02%	87.45%	87.29%	85.70%	86.20%	87.90%	88.35%	81.57%	83.12%
EBITDA Margin	57.10%	58.98%	51.79%	53.15%	39.10%	50.51%	-28.68%	57.32%	51.44%	55.34%	46.40%
Operating Margin	44.81%	44.31%	39.56%	44.21%	27.54%	37.71%	-36.21%	46.90%	41.71%	50.70%	43.85%
EBIT Margin	50.41%	52.31%	44.45%	45.46%	29.53%	42.24%	-37.03%	48.72%	43.71%	54.33%	45.43%
Profit (Net Income) Margin	40.12%	39.44%	34.10%	33.24%	23.63%	31.51%	-29.96%	37.92%	34.64%	41.92%	39.74%
Tax Burden Percent	79.59%	75.40%	76.71%	73.12%	80.01%	74.60%	80.91%	77.84%	79.24%	77.17%	87.47%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	20.41%	24.60%	23.29%	26.88%	19.99%	25.40%	0.00%	22.16%	20.76%	22.83%	12.53%
Return on Invested Capital (ROIC)	89.71%	77.82%	66.79%	67.46%	43.05%	95.02%	-77.25%	102.01%	81.58%	952.71%	388.69%
ROIC Less NNEP Spread (ROIC-NNEP)	88.36%	75.35%	65.15%	67.06%	42.39%	93.36%	-74.82%	101.31%	80.80%	952.01%	388.32%
Return on Net Nonoperating Assets (RNNOA)	-60.65%	-46.83%	-38.15%	-38.68%	-22.45%	-61.38%	47.17%	-65.67%	-50.48%	-919.00%	-356.96%
Return on Equity (ROE)	29.06%	30.99%	28.64%	28.78%	20.60%	33.64%	-30.08%	36.34%	31.10%	33.71%	31.72%
Cash Return on Invested Capital (CROIC)	104.88%	91.46%	68.11%	18.82%	4.21%	-140.92%	-124.57%	-60.83%	-64.63%	1,072.51%	402.80%
Operating Return on Assets (OROA)	34.65%	38.93%	34.54%	34.34%	23.05%	39.78%	-34.57%	41.50%	34.27%	37.94%	31.32%
Return on Assets (ROA)	27.58%	29.35%	26.50%	25.11%	18.44%	29.68%	-27.97%	32.31%	27.16%	29.28%	27.39%
Return on Common Equity (ROCE)	29.06%	30.99%	28.64%	28.78%	20.60%	33.64%	-30.08%	36.34%	31.10%	33.71%	31.72%
Return on Equity Simple (ROE_SIMPLE)	24.85%	0.00%	21.61%	11.20%	11.60%	0.00%	17.80%	30.79%	29.79%	0.00%	24.78%
Net Operating Profit after Tax (NOPAT)	50	47	39	40	22	31	-26	36	28	24	22
NOPAT Margin	35.66%	33.41%	30.35%	32.33%	22.03%	28.13%	-25.35%	36.50%	33.06%	39.12%	38.36%
Net Nonoperating Expense Percent (NNEP)	1.35%	2.47%	1.63%	0.40%	0.66%	1.65%	-2.43%	0.71%	0.78%	0.70%	0.37%
Return On Investment Capital (ROIC_SIMPLE)	6.35%	6.51%	-	-	-	8.02%	-	-	-	7.91%	-
Cost of Revenue to Revenue	12.67%	15.26%	14.98%	12.55%	12.71%	14.30%	13.80%	12.10%	11.65%	18.43%	16.88%
SG&A Expenses to Revenue	33.17%	31.16%	35.65%	33.19%	47.65%	38.02%	32.68%	28.52%	34.81%	23.19%	23.84%
R&D to Revenue	2.75%	2.68%	2.55%	2.43%	2.62%	1.78%	81.47%	3.97%	4.17%	6.74%	14.52%
Operating Expenses to Revenue	42.53%	40.43%	45.46%	43.24%	59.75%	47.99%	122.42%	41.01%	46.64%	30.88%	39.27%
Earnings before Interest and Taxes (EBIT)	71	74	57	56	29	47	-38	49	37	33	26
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	81	84	67	65	39	56	-29	57	44	34	27
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.71	3.42	3.57	3.01	3.03	4.62	3.57	3.80	5.25	6.44	4.89
Price to Tangible Book Value (P/TBV)	4.55	4.36	4.77	4.22	4.51	9.25	6.87	7.14	11.71	7.22	5.57
Price to Revenue (P/Rev)	5.51	5.06	5.12	4.21	4.13	4.50	3.58	4.71	6.83	9.04	6.88
Price to Earnings (P/E)	14.92	15.19	16.52	26.85	26.10	25.10	20.08	12.34	17.62	23.30	19.71
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	6.70%	6.58%	6.05%	3.72%	3.83%	3.98%	4.98%	8.10%	5.67%	4.29%	5.07%
Enterprise Value to Invested Capital (EV/IC)	12.36	10.34	9.34	6.55	5.83	7.01	5.18	6.35	8.65	808.16	76.07
Enterprise Value to Revenue (EV/Rev)	4.38	3.97	4.13	3.32	3.34	4.11	3.19	4.12	6.25	7.64	5.54
Enterprise Value to EBITDA (EV/EBITDA)	7.90	7.68	8.41	11.07	11.26	12.86	10.57	7.74	12.11	15.45	12.48
Enterprise Value to EBIT (EV/EBIT)	9.05	9.02	10.08	15.40	15.92	17.33	13.76	8.61	12.87	15.64	12.58
Enterprise Value to NOPAT (EV/NOPAT)	13.25	13.19	14.46	23.03	23.24	24.97	19.08	11.31	16.73	20.27	16.03
Enterprise Value to Operating Cash Flow (EV/OCF)	8.73	8.13	8.47	7.32	8.40	11.41	8.69	10.04	13.40	14.11	11.17
Enterprise Value to Free Cash Flow (EV/FCFF)	10.50	10.10	13.35	36.78	154.87	0.00	0.00	0.00	0.00	17.36	13.95
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.69	-0.62	-0.59	-0.58	-0.53	-0.66	-0.63	-0.65	-0.62	-0.97	-0.92
Leverage Ratio	1.15	1.18	1.17	1.17	1.18	1.23	1.21	1.15	1.18	1.21	1.19
Compound Leverage Factor	1.15	1.18	1.17	1.17	1.18	1.23	1.21	1.15	1.18	1.21	1.19
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	17.55	14.11	14.68	13.13	13.66	14.98	12.78	14.39	15.91	17.33	14.32
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.14	5.17	5.11	5.14	5.09	2.88	3.32	4.59	3.51	5.57	6.18
Quick Ratio	5.84	4.83	4.75	4.69	4.66	2.51	2.92	4.22	3.20	5.36	5.94
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	97	93	50	16	-29	-201	-227	-140	-135	37	32
Operating Cash Flow to CapEx	0.00%	80,542.05%	28,135.52%	641,350.00%	16,042.71%	59,836.56%	70,512.50%	0.00%	16,310.81%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.69	0.74	0.78	0.76	0.78	0.94	0.93	0.85	0.78	0.70	0.69
Accounts Receivable Turnover	8.12	8.27	8.66	8.69	8.76	12.45	12.14	11.57	11.67	25.11	24.03
Inventory Turnover	3.74	3.91	4.34	4.03	3.60	4.63	5.86	4.61	4.24	4.69	4.34
Fixed Asset Turnover	419.82	385.83	358.91	357.59	317.28	390.01	336.94	285.80	232.11	237.21	209.23
Accounts Payable Turnover	6.92	4.39	7.80	10.04	7.99	5.54	13.29	12.72	9.02	10.20	11.57
Days Sales Outstanding (DSO)	44.98	44.16	42.14	41.99	41.66	29.31	30.06	31.56	31.28	14.53	15.19
Days Inventory Outstanding (DIO)	97.67	93.27	84.14	90.67	101.32	78.84	62.31	79.22	86.17	77.87	84.13
Days Payable Outstanding (DPO)	52.75	83.21	46.81	36.36	45.68	65.92	27.47	28.69	40.49	35.78	31.55
Cash Conversion Cycle (CCC)	89.90	54.23	79.47	96.29	97.30	42.23	64.90	82.09	76.96	56.62	67.77
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	189	189	204	220	236	234	215	197	185	2.03	14
Invested Capital Turnover	2.52	2.33	2.20	2.09	1.95	3.38	3.05	2.79	2.47	24.35	10.13
Increase / (Decrease) in Invested Capital	-46	-45	-11	23	50	232	201	176	163	-14	-9.89
Enterprise Value (EV)	2,340	1,950	1,902	1,441	1,374	1,638	1,112	1,247	1,604	1,637	1,063
Market Capitalization	2,945	2,489	2,360	1,830	1,699	1,792	1,246	1,426	1,752	1,936	1,319
Book Value per Share	$6.54	$6.10	$5.57	$5.15	$4.81	$3.64	$3.27	$3.54	$3.16	$2.89	$2.63
Tangible Book Value per Share	$5.33	$4.79	$4.17	$3.67	$3.23	$1.82	$1.70	$1.88	$1.42	$2.57	$2.30
Total Capital	794	728	661	609	561	388	349	375	334	300	270
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-605	-539	-457	-389	-326	-154	-134	-179	-148	-298	-256
Capital Expenditures (CapEx)	0.00	0.09	0.26	0.01	0.20	0.09	0.06	0.00	0.07	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-6.59	-15	-8.73	6.42	15	5.63	13	9.68	-6.05	-35	-24
Debt-free Net Working Capital (DFNWC)	574	503	434	382	325	143	134	188	142	263	232
Net Working Capital (NWC)	574	503	434	382	325	143	134	188	142	263	232
Net Nonoperating Expense (NNE)	-6.30	-8.55	-4.83	-1.13	-1.57	-3.74	4.73	-1.41	-1.35	-1.70	-0.79
Net Nonoperating Obligations (NNO)	-605	-539	-457	-389	-326	-154	-134	-179	-148	-298	-256
Total Depreciation and Amortization (D&A)	9.46	9.46	9.45	9.44	9.43	9.14	8.57	8.57	6.60	0.62	0.55
Debt-free, Cash-free Net Working Capital to Revenue	-1.23%	-2.97%	-1.90%	1.48%	3.56%	1.41%	3.80%	3.19%	-2.36%	-16.42%	-12.74%
Debt-free Net Working Capital to Revenue	107.37%	102.28%	94.16%	87.95%	79.02%	35.98%	38.52%	62.21%	55.44%	122.88%	120.79%
Net Working Capital to Revenue	107.37%	102.28%	94.16%	87.95%	79.02%	35.98%	38.52%	62.21%	55.44%	122.88%	120.79%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.47	$0.46	$0.37	$0.35	$0.20	$0.32	($0.29)	$0.36	$0.28	$0.24	$0.22
Adjusted Weighted Average Basic Shares Outstanding	121.47M	118.46M	118.93M	118.18M	116.81M	106.28M	106.57M	106.26M	105.56M	103.37M	103.32M
Adjusted Diluted Earnings per Share	$0.45	$0.44	$0.35	$0.33	$0.19	$0.33	($0.29)	$0.33	$0.26	$0.23	$0.20
Adjusted Weighted Average Diluted Shares Outstanding	126.96M	124.94M	125.41M	124.66M	123.40M	113.75M	106.57M	113.67M	113.99M	111.38M	111.99M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	121.98M	121.45M	119.27M	118.69M	118.12M	117.86M	106.61M	106.58M	106.08M	105.65M	104.07M
Normalized Net Operating Profit after Tax (NOPAT)	50	47	39	40	22	31	-26	36	28	24	22
Normalized NOPAT Margin	35.66%	33.41%	30.35%	32.33%	22.03%	28.13%	-25.35%	36.50%	33.06%	39.12%	38.36%
Pre Tax Income Margin	50.41%	52.31%	44.45%	45.46%	29.53%	42.24%	-37.03%	48.72%	43.71%	54.33%	45.43%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.18%	0.21%	0.43%	0.45%	0.00%	0.00%	0.00%	4.38%	8.31%	14.92%

Frequently Asked Questions About Catalyst Pharmaceuticals' Financials

When does Catalyst Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Catalyst Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Catalyst Pharmaceuticals' net income changed over the last 9 years?

Catalyst Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $163.89 million in 2024, falling from -$20.23 million in 2015. The previous period was $71.41 million in 2023. See where experts think Catalyst Pharmaceuticals is headed by visiting Catalyst Pharmaceuticals' forecast page.

What is Catalyst Pharmaceuticals's operating income?

Catalyst Pharmaceuticals's total operating income in 2024 was $195.12 million, based on the following breakdown:

Total Gross Profit: $422.89 million
Total Operating Expenses: $227.77 million

How has Catalyst Pharmaceuticals revenue changed over the last 9 years?

Over the last 9 years, Catalyst Pharmaceuticals' total revenue changed from $0.00 in 2015 to $491.73 million in 2024, a change of 49,173,400,000.0%.

How much debt does Catalyst Pharmaceuticals have?

Catalyst Pharmaceuticals' total liabilities were at $123.78 million at the end of 2024, a 50.5% increase from 2023, and a 2,576.2% increase since 2015.

How much cash does Catalyst Pharmaceuticals have?

In the past 9 years, Catalyst Pharmaceuticals' cash and equivalents has ranged from $13.89 million in 2016 to $517.55 million in 2024, and is currently $517.55 million as of their latest financial filing in 2024.

How has Catalyst Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Catalyst Pharmaceuticals' book value per share changed from 0.67 in 2015 to 6.10 in 2024, a change of 810.8%.

Related Companies

This page (NASDAQ:CPRX) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Catalyst Pharmaceuticals (CPRX) Financials

Frequently Asked Questions About Catalyst Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Catalyst Pharmaceuticals (CPRX) Financials

Annual Income Statements for Catalyst Pharmaceuticals

Quarterly Income Statements for Catalyst Pharmaceuticals

Annual Cash Flow Statements for Catalyst Pharmaceuticals

Quarterly Cash Flow Statements for Catalyst Pharmaceuticals

Annual Balance Sheets for Catalyst Pharmaceuticals

Quarterly Balance Sheets for Catalyst Pharmaceuticals

Annual Metrics And Ratios for Catalyst Pharmaceuticals

Quarterly Metrics And Ratios for Catalyst Pharmaceuticals

Frequently Asked Questions About Catalyst Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools